Siguret V - Search Results

1

FXa-α2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo.

Jourdi G, Gouin-Thibault I, Siguret V, Gandrille S, Gaussem P, Le Bonniec B. Jourdi G, et al. Among authors: siguret v. Thromb Haemost. 2018 Sep;118(9):1535-1544. doi: 10.1055/s-0038-1667014. Epub 2018 Aug 2. Thromb Haemost. 2018. PMID: 30071567

2

Response to DDAVP stimulation in thirteen patients with Buerger's disease.

Siguret V, Alhenc-Gelas M, Aiach M, Fiessinger JN, Gaussem P. Siguret V, et al. Thromb Res. 1997 Apr 1;86(1):85-7. doi: 10.1016/s0049-3848(97)00049-2. Thromb Res. 1997. PMID: 9172291 No abstract available.

3

[Evaluation of hemostasis in venous thromboembolism pathology].

Gaussem P, Siguret V, Aiach M. Gaussem P, et al. Among authors: siguret v. Ann Biol Clin (Paris). 1998 Jan-Feb;56(1):49-56. Ann Biol Clin (Paris). 1998. PMID: 9754222 Free article. Review. French.

4

[Metastatic cancer in an 82 year old woman: bone marrow infiltration and disseminated intravascular coagulation].

Niel F, Gaussem P, Andreux MH, Bérigaud S, Andreux JP, Siguret V. Niel F, et al. Among authors: siguret v. Ann Biol Clin (Paris). 1998 Sep-Oct;56(5):580-3. Ann Biol Clin (Paris). 1998. PMID: 9769500 Free article. French. No abstract available.

5

Factor VII qualitative deficiency and pregnancy.

Siguret V, Jault T, Dreyfus M, Gallais Y, Andreux JP, Pathier D, Gaussem P. Siguret V, et al. Thromb Haemost. 1998 Oct;80(4):710-2. Thromb Haemost. 1998. PMID: 9799001 No abstract available.

6

Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years old.

Le Blanche AF, Siguret V, Settegrana C, Bohus S, Le Masne de Chermont E, Andreux JP, Gaussem P. Le Blanche AF, et al. Among authors: siguret v. Angiology. 1999 Nov;50(11):873-82. doi: 10.1177/000331979905001101. Angiology. 1999. PMID: 10580351

7

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.

Siguret V, Pautas E, Février M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P. Siguret V, et al. Thromb Haemost. 2000 Nov;84(5):800-4. Thromb Haemost. 2000. PMID: 11127859

8

[Monitoring of tinzaparin in a ten day treatment dose in elderly patients].

Pautas E, Siguret V, d'Urso M, Laurent M, Gaussem P, Février M, Durand-Gasselin B. Pautas E, et al. Among authors: siguret v. Rev Med Interne. 2001 Feb;22(2):120-6. doi: 10.1016/s0248-8663(00)00301-5. Rev Med Interne. 2001. PMID: 11234669 Clinical Trial. French.

9

Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days.

Gouin-Thibault I, Pautas E, Depasse F, Andreux JP, Siguret V. Gouin-Thibault I, et al. Among authors: siguret v. J Thromb Haemost. 2003 Dec;1(12):2694-5. doi: 10.1111/j.1538-7836.2003.0543k.x. J Thromb Haemost. 2003. PMID: 14675115 Free article. No abstract available.

10

[Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].

Dewulf G, Gouin I, Pautas E, Gaussem P, Chaïbi P, Andreux JP, Siguret V. Dewulf G, et al. Among authors: siguret v. Ann Biol Clin (Paris). 2004 Mar-Apr;62(2):197-202. Ann Biol Clin (Paris). 2004. PMID: 15047472 Free article. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters